Androgen therapy in Fanconi anemia: A retrospective analysis of 30 years in Germany. (2nd January 2016)

• Record Type: Journal Article
• Authors: Paustian, Laura; Chao, Mwe Mwe; Hanenberg, Helmut; Schindler, Detlev; Neitzel, Heidemarie; Kratz, Christian Peter; Ebell, Wolfram
• Is Part Of: Pediatric hematology and oncology. Volume 33:Number 1(2016)
• Page Start: 5
• Page End: 12
• Publication Date: 2016-01-02
• Subjects: Androgen therapy -- bone marrow failure -- Fanconi anemia; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Hematologic Diseases -- Child; Hematologic Diseases -- Infant; Neoplasms -- Child; 618.9215
• DOI: 10.3109/08880018.2015.1129567
• Languages: English
• ISSNs: 0888-0018

Abstract

ABSTRACT: A substantial number of individuals with Fanconi anemia (FA) develop bone marrow failure and are treated with androgen therapy in order to increase blood counts. The authors retrospectively identified 70 patients who received androgen therapy any time between July 1976 and September 2014. Among these patients, 37 had medical records for analysis. Twenty-five of the 37 (68%) patients had response in hemoglobin level ( n = 25), platelet count ( n = 21), and/or absolute neutrophil count ( n = 13). The median rise in hemoglobin was 6.5 mg/dL, platelet count 70, 000/mm 3, and absolute neutrophil count (ANC) 1530/μL. The majority of patients ( n = 22) had a response in 2 or more blood parameters. Reasons for discontinuation of therapy included development of cytogenetic aberrations ( n = 9), lack of response ( n = 7), hepatic adenoma ( n = 6), progression to myelodysplastic syndrome/acute myeloid leukemia ( n = 3), stabilization of blood parameters ( n = 3), resolution of cytopenia secondary to mosaicism ( n = 1), virilization ( n = 1), development of anogenital carcinoma ( n = 1), inaccessibility of medication ( n = 1), and unknown ( n = 1). Four patients at last follow-up remain on androgen therapy. These results highlight that androgen therapy can significantly improve blood counts for many FA patients, but progression of underlying bone marrow disease and development of liver adenomas requires careful monitoring.